Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-30 + GVD in Relapsed/Refractory Hodgkin Lymphoma
NCT00337194Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2006
- Primary completion
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iratumumab in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Started Apr 2006; status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00337194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337194.